Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ICP-332 in prurigo nodularis
2025-523404-74-00Phase 2Authorised
- Sponsor
- InnoCare Pharma
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in prurigo nodularis (PN) comparing ICP-332 dose-ranging arms with Placebo (2 arms). Primary endpoint: Percent change from baseline of weekly average in Peak Pruritus Numeric Rating Scale at Week 16. Planned start May 2026; status: authorised.
02
Drugs
soficitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2025-523404-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523404-74-00.